Facebook
Twitter
Telegram
Report an ErrorPhathom Pharmaceuticals Balance Sheet 2011-2024 | PHAT
Annual Balance Sheet Phathom Pharmaceuticals
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-243 M | -59.4 M | -93.1 M | -241 M | -220 M | 1.07 M | - | - | - | - | - | - | - |
Long Term Debt |
138 M | 95.3 M | 89.7 M | 39.6 M | 22.8 M | - | - | - | - | - | - | - | - |
Long Term Debt Current |
726 K | 708 K | 487 K | 474 K | 161 K | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | 45.3 M | 25.5 M | - | - | - | - | - | - | - | - |
Total Current Liabilities |
38.8 M | 26.2 M | 18.9 M | 55.5 M | 3.75 M | - | - | - | - | - | - | - | - |
Total Liabilities |
487 M | 240 M | 117 M | 101 M | 29.2 M | 2.19 M | - | - | - | - | - | - | - |
Deferred Revenue |
7.11 M | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-929 M | -727 M | -529 M | -385 M | -256 M | -1.29 M | - | - | - | - | - | - | - |
Total Assets |
414 M | 165 M | 189 M | 295 M | 257 M | 902 K | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
381 M | 155 M | 183 M | 287 M | 244 M | - | - | - | - | - | - | - | - |
Book Value |
-72.8 M | -74.8 M | 72.2 M | 194 M | 228 M | -1.29 M | - | - | - | - | - | - | - |
Total Shareholders Equity |
-72.8 M | -74.8 M | 72.2 M | 194 M | 228 M | -1.29 M | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet Phathom Pharmaceuticals
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
99.3 M | 97.8 M | 96.6 M | 95.3 M | 93.9 M | - | 91 M | 89.7 M | 88.3 M | 37.3 M | 35.6 M | 39.6 M | 39.6 M | 39.6 M | 39.6 M | 22.8 M | 22.8 M | 22.8 M | 635 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
255 M | 247 M | 234 M | 240 M | 228 M | - | 111 M | 117 M | 125 M | 82.5 M | 82 M | 101 M | 101 M | 101 M | 101 M | 29.2 M | 29.2 M | 29.2 M | 29.2 M | 2.19 M | 2.19 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
2.39 M | 276 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-849 M | -806 M | -765 M | -727 M | -672 M | - | -570 M | -529 M | -494 M | -457 M | -420 M | -385 M | -385 M | -385 M | -385 M | -256 M | -256 M | -256 M | -256 M | -1.29 M | -1.29 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
237 M | 265 M | 144 M | 165 M | 202 M | - | 149 M | 189 M | 228 M | 215 M | 246 M | 295 M | 295 M | 295 M | 295 M | 257 M | 257 M | 257 M | 257 M | 902 K | 902 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
214 M | 249 M | 130 M | 155 M | 197 M | - | 138 M | 183 M | 225 M | 210 M | 238 M | 287 M | 287 M | 287 M | 287 M | 244 M | 244 M | 244 M | 244 M | 879 K | 879 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
-17.8 M | 17.6 M | -90.2 M | -74.8 M | -26.4 M | - | 38 M | 72.2 M | 103 M | 132 M | 164 M | 194 M | 194 M | 194 M | 194 M | 228 M | 228 M | 228 M | 228 M | -1.29 M | -1.29 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
-17.8 M | 17.6 M | -90.2 M | -74.8 M | -26.4 M | -7 M | 38 M | 72.2 M | 103 M | 132 M | 164 M | 194 M | 194 M | 194 M | 194 M | 228 M | 228 M | 228 M | 228 M | -1.29 M | -1.29 M | -512 K | -252 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency